Suppr超能文献

复发性小肝细胞癌患者的低分割放射治疗挽救治疗。

Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma.

机构信息

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e603-7. doi: 10.1016/j.ijrobp.2011.09.053. Epub 2011 Dec 28.

Abstract

PURPOSE

To investigate the rates of tumor response and local control in patients with recurrent small hepatocellular carcinoma (HCC) treated with hypofractionated radiotherapy (RT) as a salvage treatment and to evaluate treatment-related toxicities.

METHODS AND MATERIALS

Between 2006 and 2009, a total of 20 patients with recurrent small HCC were treated with hypofractionated RT after the failure of previous treatment. The eligibility criteria for hypofractionated RT were as follows: 1) HCC less than 5 cm, 2) HCC not adjacent to critical organs, 3) HCC without portal vein tumor thrombosis, and 4) less than 15% of normal liver volume that would be irradiated with 50% of prescribed dose. The RT dose was 50 Gy in 10 fractions. The tumor response was determined by CT scans performed 3 months after the end of RT.

RESULTS

The median follow-up period after RT was 22 months. The overall survival rates at 1 and 2 years were 100% and 87.9%, respectively. Complete response (CR) was achieved in seven of 20 lesions (35%) evaluated by CT scans performed 3 months after the end of RT. In-field local control was achieved in 85% of patients. Fourteen patients (70%) developed intra-hepatic metastases. Six patients developed grade 1 nausea or anorexia during RT, and two patients had progression of ascites after RT. There was no grade 3 or greater treatment-related toxicities.

CONCLUSIONS

The current study showed a favorable outcome with respect to hypofractionated RT for small HCC. Partial liver irradiation with 50 Gy in 10 fractions is considered tolerable without severe complications.

摘要

目的

研究接受分割剂量放疗(RT)作为挽救治疗的复发性小肝细胞癌(HCC)患者的肿瘤反应和局部控制率,并评估与治疗相关的毒性。

方法和材料

2006 年至 2009 年间,共有 20 例复发性小 HCC 患者在先前治疗失败后接受分割剂量 RT 治疗。接受分割剂量 RT 的合格标准如下:1)HCC 小于 5cm,2)HCC 不紧邻关键器官,3)HCC 无门静脉肿瘤血栓形成,以及 4)50%处方剂量照射时肝脏的正常体积小于 15%。RT 剂量为 50Gy/10 次。RT 结束后 3 个月通过 CT 扫描确定肿瘤反应。

结果

RT 后中位随访时间为 22 个月。RT 后 1 年和 2 年的总生存率分别为 100%和 87.9%。20 个可评估病灶中,有 7 个病灶(35%)通过 CT 扫描显示完全缓解(CR)。85%的患者实现了肿瘤靶区的局部控制。14 例患者(70%)发生肝内转移。6 例患者在 RT 期间出现 1 级恶心或厌食,2 例患者在 RT 后出现腹水进展。无 3 级或更高级别的与治疗相关的毒性。

结论

目前的研究显示,分割剂量 RT 治疗小 HCC 的结果良好。50Gy/10 次的部分肝脏照射被认为是可耐受的,没有严重的并发症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验